HHS announced the rule in May 2019. The department argued that patients deserved transparency and that forcing drugmakers to put prices in ads would incentivize them to create lower list prices.
Merck, Eli Lilly and Amgen filed a lawsuit in June 2019 challenging the lawfulness of the rule, arguing it violated the Administrative Procedure Act because the rule exceeds HHS’ authority.
The U.S. Court of Appeals for the District of Columbia Circuit ruled in favor of the drugmakers, saying that HHS lacked the authority to establish the rule and that it acted “unreasonably” in making it.
More articles on pharmacy:
FDA warns of potential drug interaction with remdesivir
Steroid could reduce COVID-19 deaths: 5 things to know
Walmart buys prescription management tech from CareZone
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
